This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Mark Your Calendar for Next Year's Event!
May 9-12, 2022Hynes Convention Center, Boston

Eric van der Veer, Ph.D.
Chief Scientific Officer at Hybridize Therapeutics


Eric studied Chemistry at the University of Amsterdam (M.Sc), and pursued a Ph.D. degree in Biochemistry at the University of Western Ontario (Canada). He returned to the Netherlands (LUMC) and started his own research group specializing in RNA biology of healthy and diseased cells, yielding publications in Nature Communications, European Heart Journal and Circulation Research. For his work, he was awarded the Irvine H. Page Award by the American Heart Association. In 2015, he conceived a novel method of targeting polyomaviruses. To further develop this concept and transition the therapy to the clinic, he left the LUMC in 2019 and founded Hybridize Therapeutics.

Agenda Sessions

  • ROOM 205A: A Novel, RNA-based Anti-viral Approach to Limit BK Virus Propagation in Immunocompromised Patients